1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

GBY.DE
Sangamo Therapeutics, Inc.DE flagDeutsche Börse
5.05
EUR
-0.20
- -
884.70MMarket Cap
Sangamo Therapeutics, Inc.
GBY.DE
(Deutsche Börse)

Recent

price

5.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
0.4
0.53
0.46
0.2
0.41
0.43
0.68
0.57
0.27
0.47
0.87
0.91
0.88
0.77
- -
- -
- -
Revenue per Share
-0.6
-0.44
-0.55
-0.71
-0.42
-0.48
-0.39
-0.58
-1.02
-0.7
-0.7
-0.85
-0.9
-1.23
- -
- -
- -
Basic EPS, GAAP
-0.44
-0.15
-0.55
-0.52
-0.17
-0.36
-0.08
-0.48
-0.94
0.1
-0.07
-1.47
1.15
-1.77
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-4.25
-4.57
-4.81
-5
-5.21
-5.39
-4.89
-5.28
-6.24
-6.33
-5.79
-5.85
-5.78
-6.6
- -
- -
- -
Book Value per Share
1.36
1.71
1.24
1.59
1.23
2.11
3.03
2.74
1.91
2.39
2.82
3.04
2.95
1.95
- -
- -
- -
Tangible Book Value per Share
41
42
45
51
53
56
67
70
71
78
97
112
134
145
- -
- -
- -
Basic Weighted Avg Shares
16
22
21
10
22
24
46
40
19
37
84
102
118
111
111
176
12
Sales/Revenue/Turnover
-156.77
-87.45
-119.85
-347.14
-102.51
-110.66
-58.38
-118.51
-374.23
-154.13
-91.35
-102.69
-109.61
-165.61
-180.85
-67.52
-1,681.69
Operating Margin (%)
1
1
1
1
1
1
1
1
1
1
2
10
13
18
21
22
16
Depreciation Expense
-24
-19
-25
-36
-22
-27
-26
-41
-72
-55
-68
-95
-121
-178
-192
-258
-250
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-150.14
-83.77
-119.46
-346.45
-102.81
-110.32
-57.59
-102.94
-369.58
-149.23
-80.91
-92.93
-102.37
-161.05
-172.76
-146.3
-2,033.68
Profit Margin (%)
54
70
54
78
60
87
170
192
136
204
332
336
516
271
189
47
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
4
25
28
41
38
44
39
34
29
LT Debt
55
72
56
80
65
122
207
192
136
188
367
433
497
375
295
83
24
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
5
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
34
31
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
178
204
208
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
94
69
40
Cash, Cash Equivalents & STI
81
54
28
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
48
40
39
Payables & Accruals
34
34
33
ST Debt
5
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.2%
-17.02%
-71.9%
Free Cash Flow
219.18%
394.08%
0.9%
Net Income, GAAP
28.64%
31.14%
34.09%
Sales/Revenue/Turnover
33.41%
17.84%
58.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
28
29
26
27
111
2023
158
7
9
2
176
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.3
-0.29
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Celularity Inc. (GXGXW)
Genflow Biosciences Plc (GENF.L)
Genfit S.A. (GNFT.PA)
ArriVent BioPharma, Inc. (AVBP)
Ensysce Biosciences, Inc. (ENSCW)
Ribomic Inc. (4591.T)
Business
Sangamo Therapeutics, Inc. (Ticker: GBY.DE) is a clinical-stage genomic medicine company that develops gene therapies, gene editing, and gene regulation technologies for the treatment of neurological diseases, hemoglobinopathies, and immunodeficiencies. The company offers a pipeline of product candidates including ST-920 (isaralgagene civaparvovec), a zinc finger nuclease-based gene-edited therapy for Fabry disease; TX200, a CAR-Treg cell therapy for kidney transplant rejection; and SB-525 (giroctocogene fitelparvovec), an AAV6 capsid-delivered gene therapy for hemophilia A developed in collaboration with Pfizer Inc. Additional programs encompass zinc finger protein transcription factors (ZFP-TFs) for prion disease and gene regulation platforms for other monogenic diseases; services include genomic medicine discovery and development using proprietary zinc finger nuclease (ZFN) and ZFP technologies. Sangamo operates primarily in the United States and Europe, targeting patients with rare genetic disorders through partnerships with pharmaceutical companies such as Pfizer, Novartis, and Kite Pharma (a Gilead Sciences subsidiary). Founded in 1995 and headquartered in Brisbane, California, the company maintains subsidiaries including Sangamo Therapeutics UK Ltd. and Sangamo BioSciences Inc. In recent developments within the last two years, Sangamo completed a strategic restructuring in 2024, including a significant reduction in workforce and pipeline prioritization to focus on neurology assets like ST-920 following positive Phase 1/2 data; entered a collaboration with Genentech (Roche) in 2024 for ZFP-TF-based therapies in neurology; licensed its capsid portfolio to Lilly in 2023 for AAV delivery technologies; and announced topline results from the STAAR study for Fabry disease in mid-2025, supporting regulatory filings.